PRSO Form 4: James Sullivan Receives 25,000 Stock Options
Rhea-AI Filing Summary
James Sullivan, Chief Financial Officer of Peraso Inc. (PRSO), reported acquisition of stock options granting the right to purchase 25,000 shares of common stock at an exercise price of $0.8399 per share, with a transaction date of 08/07/2025. The options vest at 1/36th of the shares on each monthly anniversary following 08/07/2025 and are reported as held directly by the reporting person. The filing lists a date of 08/07/2035 in the date/exercise expiration field and reports total derivative holdings of 25,000 options. The explanation clarifies the monthly vesting schedule and notes that column reporting covers only the listed derivative class.
Positive
- Reported acquisition of 25,000 stock options exercisable at $0.8399 per share
- Vesting schedule explicitly stated as 1/36th monthly following 08/07/2025
- Options are reported as held directly by the reporting person
Negative
- Table shows a $0.00 entry in a price field for the derivative security, which may require clarification
- Form 4 reporting covers only this derivative class; prior holdings or other award classes are not detailed
Insights
TL;DR: Routine executive option grant; 25,000 options at $0.8399 with monthly vesting over 36 months, direct ownership reported.
The Form 4 discloses a grant of 25,000 stock options to the CFO with an exercise price of $0.8399. The options were transacted on 08/07/2025, vest at 1/36th per month thereafter and are shown as directly owned. The filing lists 08/07/2035 in the date/exercise expiration field and reports total derivative holdings of 25,000 options for this derivative class. This is a standard long-term incentive award as reported; the Form does not disclose any cash consideration beyond the stated exercise price or other classes of outstanding awards.
TL;DR: Disclosure is specific on vesting and quantity but limited to this derivative class; no material governance red flags apparent in the record.
The filing clearly states the grant terms: 25,000 options, $0.8399 exercise price, monthly vesting at 1/36th following 08/07/2025, and direct ownership. The explanatory note clarifies column reporting conventions for derivative classes. The table shows a $0.00 entry in a price field which may reflect reporting layout rather than economic detail; the Form does not provide additional context about board approval or other outstanding award classes. Based solely on the disclosed items, this appears to be a routine equity incentive disclosure.